Lipoprotein abnormalities in chronic renal failure, nephrotic syndrome and dialysis;Poremećaji lipoproteina u kroničnom zatajenju bubrega, nefrotskom sindromu I dijalizi

Lijecnicki Vjesnik

Volumn 124, Issue 11-12, 2002, Pages 372-377

  Kes, Petar ^a,b   Reiner, Željko ^a   Brunetta, Bruna ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b KBC Zagreb   (Croatia)

Author keywords

Hyperlipidemia etiology, therapy; Kidney failure, chronic complications; Nephrotic syndrome complications; Renal dialysis

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN A;

ARTIFICIAL KIDNEY; BEHAVIOR MODIFICATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHOLESTEROL TRANSPORT; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; DIET THERAPY; DYSLIPOPROTEINEMIA; HEMODIALYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; HYPERTRIGLYCERIDEMIA; LIFESTYLE; LIPID METABOLISM; NEPHROTIC SYNDROME; PERIPHERAL VASCULAR DISEASE; PERITONEAL DIALYSIS; REVIEW;

HUMANS; HYPERLIPIDEMIAS; HYPERLIPOPROTEINEMIAS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS; NEPHROTIC SYNDROME; RENAL DIALYSIS;

EID: 0344837765     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Parfrey PS, Harnett JD, Barre PE. The natural history of myocardial disease in dialysis patients. JASN 1991;2:2-12.
2. Kunz K, Dimitrov Y, Muller S et al. Uraemic cardiomyopathy. Nephrol Dial Transplant 1998;13(Suppl 4):39-43.
3. Kes P, Drusko D, Rupčic V. Cardiovascular complications in end-stage renal disease and hemodialysis patients. Acta Med Croatica 1996;50:199-208.
4. US Renal Data System. USRDS 1995 Annual Data Report. The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda 1995.
5. Manske CL, Kasiske BL. Lipid abnormalities after renal transplantation. In: Lipids and renal disease, Keane WF, Stein JH, eds. Contemporary Issues in Nephrology, Churchill Livingstone, New York 1991, pp 37-61.
6. Collins A, Ma J, Herzog C. Acute and chronic survival of dialysis patients with acute myocardial infarction. JASN 1996;7:1476.
7. Botet JP, Senti M, Prat RJ, Pelegri A, Romero R. When to treat dyslipidaemia of patients with chronic renal failure on haemodialysis? A need to define specific guidelines. Nephrol Dial Transplant 1996;11:308-13.
8. Massy ZA, Ma JZ, Louis TA, Kasiske BL. Lipid-lowering therapy in patients with renal disease. Kidney Int 1995;48:188-98.
9. Kasiske BL. Management of lipid abnormalities in the patient with renal disease. In: Handbook of Nutrition and the Kidney, eds. Mitch WE, Klahr S. Lippincott-Raven Publishers, Philadelphia-New York 1998, pp 124-43.
10. Massy ZA, Ma JZ, Louis TA et al. Lipid-lowering therapy patients with renal disease. Kidney Int 1995;48:188-98.
11. Moorhead JF. Lipids and the pathogenesis of kidney disease. AJKD 1991; 17(Suppl 1):65-70.
12. Keane WE. The role of lipids in renal disease: Feature challenges. Kidney Int 2000;57(Suppl 75):S-27-S-31.
13. Attman PO, Alaupovic P. Lipid abnormalities in chronic renal insufficiency. Kidney Int 1991;39(Suppl 31):S-16-S-23.
14. Manzoni G, Bergesio F, Ciuti R et al. Lipoprotein abnormalities in chronic renal failure and dialysis patients. Blood Purif 1996;14:262-72.
15. Attman PO, Nyberg G, William-Olsson T, Knight-Gibson C, Alaupovic P. Dyslipoproteinemia in diabetic renal failure. Kidney Int 1992;42:1381-9.
16. Jacobsen P, Rossing K, Tarnow L et al. Progression of diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 1999;56(Suppl 71):S-101-S-105.
17. Kamanna BL, Kirschenbaum MA. Association between very low density lipoprotein and glomerular injury in obese Zucker rats. Am J Nephrol 1993;13:53-8.
18. Keane WF, Kasiske BL, O'Donnell MP, Kim Y. Hypertension, hyperlipidemia, and renal damage. AJKD 1993;21(Suppl 2):43-50.
19. Shmitz PG, Kasiske BL, O'Donnell MP, Keane WF. Lipids and progressive renal injury. Semin Nephrol 1989;9:354-69.
20. Samuelsson O, Mulec H, Knight-Gibson C et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997;12:1908-15.
21. Ravid M, Neumann L, Lishner M. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: Effects of ACE inhibitors. Kidney Int 1995;47:907-10.
22. Keane WF, Mulcahy WS, Kasiske BL et al. Hyperlipidemia and progressive renal disease. Kidney Int 1991;39(Suppl 31):S-41-S-48.
23. Magil AB. Interstitial foam cells and oxidized lipoprotein in human glomerular disease. Mod Pathol 1999;12:33-40.
24. Lam KSL, Cheng IKP, Janus ED, Pang RWC. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995;38:604-9.
25. Chan PC, Robinson JD, Yeung WC et al. Lovastatin in glomerulonephritis patients with hyperlipidemia and heavy proteinuria. Nephrol Dial Transplant 1992;7:93-9.
26. Rayner BL, Byrne MJ, van Zyl Smith R. A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clin Nephrol 1996;46:219-24.
27. Nielsen S, Schmitz O, Moller N et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 diabetic patients with microalbuminuria. Diabetologia 1993;36:1079-83.
28. Jungers P, Massy ZA, Nguyen Khoa T et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: A prospective study. Nephrol Dial Transplant 1997;12:2597-602.
29. Kasiske BL. Hyperlipidemia in patients with chronic renal failure. AJKD 1998;32(Suppl 3):S-142-156.
30. Kaysen GA. Hyperlipidemia of the nephrotic syndrome. Kidney Int 1991; 39(Suppl 31):S-8-S-15.
31. Joven J, Villabona C, Vilella E. Pattern of hyperlipoproteinemia in human nephrotic syndrome: Influence of renal failure and diabetes mellitus. Nephron 1993;64:565-9.
32. Hirano T. Lipoprotein abnormalities in diabetic nephropathy. Kidney Int 1999;56(Suppl 71):S-22-S-24.
33. Appel GB, Blum CB, Chein S, Koopman MG, Appel AS. The hyperlipidemia ofthe nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity. N Engl J Med 1985;312:1544-8.
34. Radhakrishnan J, Appel AS, Valeri A, Appel GB. The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. AJKD 1993;22:135-9.
35. Yamaguchi A, Fukuhara Y, Yamamoto S et al. Oncotic pressure regulates gene transcription of albumin and apolipoprotein B in cultured rat hepatoma cells. Am J Physiol 1992;263:C397.
36. Dairou F. Lipid disorders and cardiovascular risk in nephrology. Nephrol Dial Transplant 1998;13(Suppl 4):30-3.
37. Demant T, Mathes C, Gutlich K et al. A simultaneous study of the metabolism of apolipoprotein B and albumin in nephrotic syndrome. Kidney Int 1998;54:2064-9.
38. Vega GL, Toto RD, Grundy SM. Metabolism of low density lipoproteins in nephrotic dyslipidemia: Comparison of hypercholesterolemia alone and combined hyperlipidemia. Kidney Int 1995;47:579-62.
39. Davies RW, Staprans I, Hutchinson FN, Kaysen GA. Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest 1990;86:600-3.
40. Kaysen GA, de Sain-van der Velden MGM. New insights into lipid metabolism in the nephrotic syndrome. Kidney Int 1999;55(Suppl 71):S-18-S-21.
41. Wass V, Cameron JS. Cardiovascular disease and the nephrotic syndrome: The other site of the coin. Nephron 1981;27:58-61.
42. Hopper J, Ryan P, Lee LC et al. Lipoid nephrosis in 31 adult patients: Renal biopsy study by light, electron and fluorescence microscopy with experience in treatment. Med Baltimore 1970;49:321-41.
43. Oqvist BW, Thyssel H, Rippe B et al. Membranous glomerulonephritis. A retrospective study of 53 patients. Eur Dial Transplant Assoc 1992; Abstr. 245.
44. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993;44:638-71.
45. Gentile MG, Fellin G, Cofano F et al. Treatment of proteinuric patients with vegetarian soy diet and fish oil. Clin Nephrol 1993;40:315-8.
46. Kasiske BL, Velosa JA, Halstenson CE et al. The effects of Lovastatin in hyperlipidemic patients with the nephrotic syndrome. AJKD 1990;15:8-15.
47. Brown CD, Azrolan N, Thomas L et al. Reduction of lipoprotein(a) following treatment with lovastatin in patients with unremitting nephrotic syndrome. AJKD 1995;26:170-4.
48. Appel GB. How should the lipid abnormalities of dialysis patients be treated? Semin Dial 1995;8:15-6.
49. Elisaf MS, Bairaktari HT, Tziallos CS et al. Atherogenic lipid and lipoprotein parameters in hemodialysis patients. Dial Transplant 1995;24:642-50.
50. Pollock CA, Wyndham R, Collett PV et al. Effects of erythropoietin therapy on lipid profile in end-stage renal failure. Kidney Int 1994;45:897-902.
51. Kes P, Drusko D. The influence of erythropoietin treatment on the lipide profile in patients on long-term hemodialysis. VIII International Symposium on Nephrology at Montecatini. Montecatini Terme, Italy 1996:48 (Abstract).
52. Prata MM, Madeira C, Vicente O, Miguel MJP. Lipid profile in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 1998;13:1345-7.
53. Elisaf MS, Germanos NP, Bairaktari HT et al. Effects of conventional vs. low-molecular-weight heparin on lipid profile in hemodialysis patients. Am J Nephrol 1997;17:153-7.
54. Deuber HJ, Schulz W. Reduced lipid concentrations during four years of dialysis with low molecular weight heparin. Kidney Int 1991;40:496-500.
55. de Precigout V, Higueret D, Larroumet N et al. Improvement in lipid profiles and tryglyceride removal in patients on polyamide membrane hemodialysis. Blood Purif 1996;14:170-6.
56. Seres DS, Strain GW, Hashim SA, Goldberg IJ, Levin NW. Improvement of plasma lipoprotein profiles during high-flux dialysis. JASN 1993;3:1049-15.
57. Jung K, Scheifler A, Schulze BD, Scholz M. Lower serum high-density lipoprotein-cholesterol concentration in patients undergoing maintenance hemodialysis with acetate then with bicarbonate. AJKD 1995;25:584-8.
58. Ginsburg ES, Walsh B, Greenberg L et al. Effects of estrogen replacement therapy on the lipoprotein profile in postmenopausal women with ESRD. Kidney Int 1998;54:1344-6.
59. O'Neal D, Lee P, Murphy B, Best J. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. AJKD 1996;27:84-91.
60. Lindholm B, Norbeek HE. Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis. Acta Med Scand 1986;220:143-51.
61. Kagan A, Bar-Khayim Y, Schafer Z, Fainaru M. Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein leakage and its impact on plasma lipid levels. Kidney Int 1990;37:980-90.
62. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Mori H. Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int 1992;41:1653-61.
63. Webb AT, Brown EA. Prevalence of symptomatic arterial disease and risk factors for its development in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1993;13(Suppl 2):S-406-S-408.
64. Jacobs RH, Lal SM, Nolph KD. Lipid-lowering effects of lovastatin in CAPD patients. Adv Perit Dial 1993;9:288-90.